Last updated: August 12, 2026
The U.S. hydrocodone bitartrate and acetaminophen market is a mature, genericized opioid market with low product-level pricing, declining prescription volume, and persistent regulatory pressure. Commercial value is concentrated in generic supply contracts, pharmacy distribution, hospital procurement, and controlled-substance manufacturing capacity rather than branded pricing power. The original Vicodin, Norco, and Lortab franchises no longer provide meaningful patent-protected revenue.
What is the market status of hydrocodone bitartrate and acetaminophen?
Hydrocodone bitartrate and acetaminophen is an immediate-release oral combination opioid used for short-term treatment of moderate to severe pain. The products are available primarily as generic tablets, capsules, and oral solutions in several strength combinations.
Common strengths include:
| Hydrocodone/APAP strength |
Typical product format |
| 5 mg/300 mg |
Tablet |
| 5 mg/325 mg |
Tablet |
| 7.5 mg/300 mg |
Tablet |
| 7.5 mg/325 mg |
Tablet |
| 10 mg/300 mg |
Tablet |
| 10 mg/325 mg |
Tablet |
| 2.5 mg/325 mg |
Tablet |
| 7.5 mg/325 mg or 10 mg/325 mg |
Oral solution or tablet, depending on manufacturer |
Hydrocodone is present as hydrocodone bitartrate, while acetaminophen supplies the non-opioid analgesic component. The product is regulated as a Schedule II controlled substance in the United States. The Drug Enforcement Administration moved hydrocodone combination products from Schedule III to Schedule II in October 2014, increasing prescribing, dispensing, recordkeeping, and refill controls (Drug Enforcement Administration, 2014).
The market is dominated by abbreviated new drug application products. Major generic manufacturers and suppliers have included Amneal Pharmaceuticals, Hikma Pharmaceuticals, Mallinckrodt, Rhodes Pharmaceuticals, Teva Pharmaceuticals, Endo Pharmaceuticals, Sun Pharma, Sandoz, and various contract manufacturers. Product availability changes by strength, supplier, wholesaler inventory, and manufacturing allocation.
How large is the hydrocodone acetaminophen market?
No major manufacturer reports hydrocodone bitartrate and acetaminophen as a separate revenue line in public filings. The market is embedded within broader generic pharmaceuticals, controlled substances, pain medicines, or U.S. pharmaceutical sales categories.
The financial market has three defining characteristics:
- Prescription volume has contracted materially from its peak.
- Generic competition has reduced unit pricing.
- Supply constraints and controlled-substance quotas can create temporary price increases without restoring durable brand economics.
U.S. opioid prescribing peaked in the early 2010s. The Centers for Disease Control and Prevention reported a national opioid prescribing rate of 81.3 prescriptions per 100 persons in 2012, declining to 43.2 per 100 persons in 2022 (Centers for Disease Control and Prevention, 2024). Hydrocodone products were among the largest contributors to the earlier prescription volume.
The market remains commercially relevant because hydrocodone is still widely used in acute dental, postoperative, musculoskeletal, and injury-related pain. Its share of opioid prescribing has declined as clinicians have reduced opioid exposure, substituted non-opioid analgesics, or shifted toward other short-duration products.
Public data do not support a reliable standalone estimate for annual U.S. hydrocodone/APAP revenue. Any market-size estimate that combines branded sales, generic sales, prescription claims, and institutional purchasing without separating product strengths and formulations can materially overstate the addressable commercial opportunity.
When did hydrocodone acetaminophen lose exclusivity?
The principal hydrocodone/APAP brands lost commercial exclusivity years ago.
| Brand |
Historical manufacturer or marketer |
Exclusivity position |
| Vicodin |
Abbott Laboratories and later other marketers |
Legacy product; no current meaningful patent exclusivity |
| Norco |
Watson Pharmaceuticals, now associated with Actavis/Teva legacy operations |
Genericized |
| Lortab |
UCB and later other marketers |
Genericized and commercially diminished |
| Generic hydrocodone/APAP |
Multiple ANDA holders |
Competitive market with no single controlling patent owner |
The products were developed and marketed before the current patent-centered specialty pharmaceutical model. Their commercial protection depended largely on brand recognition, prescriber familiarity, manufacturing scale, and distribution rather than an enduring modern patent estate.
The 300 mg and 325 mg acetaminophen presentations are not interchangeable from a labeling and manufacturing perspective, but they do not create a meaningful market-wide exclusivity barrier. The FDA encouraged manufacturers to limit prescription combination products to no more than 325 mg of acetaminophen per dosage unit because of the risk of severe liver injury associated with excessive acetaminophen exposure (U.S. Food and Drug Administration, 2011).
What patents protect hydrocodone bitartrate and acetaminophen?
No broad, commercially significant patent estate is generally associated with conventional immediate-release hydrocodone bitartrate and acetaminophen tablets.
The relevant intellectual property categories are:
| IP category |
Commercial relevance |
| Original composition patents |
Expired for conventional hydrocodone/APAP products |
| Immediate-release tablet patents |
Generally expired or no longer commercially material |
| Formulation patents |
Potentially relevant only to differentiated delivery systems or excipient systems |
| Method-of-use patents |
Limited value for a mature short-term analgesic product |
| Manufacturing patents |
May protect process details but rarely block generic tablet manufacture |
| Trademark rights |
Brand protection may remain, but does not prevent generic substitution |
| Regulatory exclusivity |
No meaningful current exclusivity for standard products |
The FDA Orange Book remains the controlling public source for patents listed against approved reference products and related regulatory exclusivity information (U.S. Food and Drug Administration, 2024a). For legacy hydrocodone/APAP products, the commercial question is generally not whether a foundational patent remains enforceable. The question is whether a specific manufacturer has a formulation, process, or product-specific patent listed against a particular approved strength or dosage form.
A patent review must be conducted at the National Drug Code, application, strength, and dosage-form level. A conclusion based only on the active ingredients can miss patents tied to a specific oral solution, extended-release formulation, abuse-deterrent technology, or manufacturing process.
What is the Orange Book status of hydrocodone acetaminophen?
The standard immediate-release hydrocodone/APAP market is largely supplied through abbreviated new drug applications referencing legacy approved products. The Orange Book does not create a single consolidated patent profile for every generic hydrocodone/APAP product.
Key regulatory points include:
- Standard immediate-release products are generally approved through ANDA pathways.
- Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
- Controlled-substance manufacturing and distribution remain subject to DEA requirements.
- Listed patents, if any, apply to the specific reference product and approved formulation.
- Generic applicants may use Paragraph IV certifications when they seek approval before listed patent expiry.
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, should be reviewed by product-specific application and strength rather than by ingredient name alone (U.S. Food and Drug Administration, 2024a).
Have companies filed Paragraph IV challenges for hydrocodone acetaminophen?
Paragraph IV litigation was commercially important during the original genericization of branded hydrocodone/APAP products. It is not the principal current market driver for standard immediate-release products because the principal brand and formulation protections have already expired.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. Under the Hatch-Waxman framework, a first-filer may become eligible for 180 days of generic drug exclusivity if statutory conditions are satisfied (U.S. Food and Drug Administration, 2024b).
For hydrocodone/APAP, current generic-entry risk is more likely to involve:
- FDA approval timing;
- DEA manufacturing quota availability;
- active pharmaceutical ingredient supply;
- product discontinuations;
- wholesaler allocation;
- state opioid-prescribing restrictions; and
- contract repricing.
A new Paragraph IV dispute would be more likely to involve a differentiated formulation, abuse-deterrent product, oral solution, or delivery technology than a conventional immediate-release tablet.
What regulatory events changed the financial trajectory?
2011 acetaminophen dose action
The FDA asked manufacturers to limit prescription combination products containing acetaminophen to 325 mg per dosage unit. The change reduced the commercial relevance of older 500 mg acetaminophen combinations and pushed the market toward 325 mg presentations (U.S. Food and Drug Administration, 2011).
2014 Schedule II rescheduling
The DEA’s 2014 rescheduling decision eliminated refills and increased administrative controls. The change affected prescriber behavior, pharmacy workflow, patient access, and dispensing economics (Drug Enforcement Administration, 2014).
Opioid prescribing restrictions
Federal and state policies reduced high-volume opioid prescribing. The CDC issued its 2016 guideline for prescribing opioids for chronic pain, followed by a 2022 updated guideline addressing acute, subacute, and chronic pain (Centers for Disease Control and Prevention, 2016, 2022).
FDA opioid action plans
The FDA has pursued risk evaluation, labeling, post-market surveillance, prescriber education, and opioid stewardship measures. These policies have increased compliance costs and reduced the probability that a conventional opioid analgesic can generate premium pricing solely through brand positioning (U.S. Food and Drug Administration, 2016).
How strong is the patent estate for hydrocodone acetaminophen?
The patent estate for conventional hydrocodone/APAP tablets is weak from a market-exclusion perspective.
| Factor |
Assessment |
| Foundational active-ingredient protection |
Expired |
| Conventional immediate-release tablet protection |
Weak or expired |
| Brand substitution barrier |
Low |
| Regulatory barrier |
Moderate |
| Controlled-substance manufacturing barrier |
Moderate to high |
| Supply-chain barrier |
Variable and sometimes significant |
| Litigation exposure for standard tablets |
Low relative to patent-protected specialty drugs |
| Pricing power |
Low |
| Abuse-deterrent formulation opportunity |
Potentially higher, but commercially uncertain |
The strongest barriers are operational rather than patent-based. A manufacturer needs compliant controlled-substance facilities, DEA quota access, validated supply chains, reliable API procurement, quality systems, and wholesaler relationships. These barriers can limit competition even when no enforceable patent blocks entry.
What generic entry risks exist?
Generic entry risk is already realized for standard hydrocodone/APAP products. The market has multiple suppliers and limited differentiation. Future entrants would primarily increase price pressure, although shortages can temporarily produce the opposite effect.
The most likely generic scenarios are:
| Scenario |
Market effect |
| New tablet ANDA approval |
Incremental price erosion and share fragmentation |
| Manufacturer discontinuation |
Temporary allocation pressure and possible price increases |
| DEA quota reduction |
Lower supply and reduced prescription fulfillment |
| API disruption |
Higher acquisition cost and intermittent shortages |
| New abuse-deterrent product |
Possible premium niche, with adoption limited by cost |
| Tighter prescribing controls |
Continued volume decline |
| Expanded non-opioid use |
Long-term substitution pressure |
The FDA has reported drug shortages and supply vulnerabilities involving multiple controlled substances. Shortages can produce revenue volatility for manufacturers with available inventory, but they do not necessarily improve long-term margins because contract pricing, procurement scrutiny, and regulatory obligations remain restrictive (U.S. Food and Drug Administration, 2024c).
Which companies are competing in the market?
Competition is fragmented across branded-generic and pure-generic suppliers. Public filings indicate that companies involved in broader opioid and generic portfolios have included:
- Teva Pharmaceuticals;
- Amneal Pharmaceuticals;
- Hikma Pharmaceuticals;
- Mallinckrodt;
- Rhodes Pharmaceuticals;
- Endo Pharmaceuticals;
- Sun Pharmaceutical Industries;
- Sandoz; and
- contract manufacturers supplying wholesalers and pharmacy chains.
Participation varies by strength and time period. A company may remain approved for a product while discontinuing active commercial distribution. FDA approval, listing in the Orange Book, and current market supply are separate conditions.
The competitive advantage is usually based on manufacturing reliability, cost control, quota access, quality performance, and distribution. Brand loyalty has limited value because pharmacists can substitute therapeutically equivalent generics subject to state law, payer rules, prescriber instructions, and inventory.
What is the revenue exposure for manufacturers?
Hydrocodone/APAP revenue exposure is strategically asymmetric.
For diversified generic manufacturers, the product is usually a small component of a broader portfolio. It can support manufacturing utilization and pharmacy relationships but rarely drives company valuation.
For controlled-substance specialists, the product can have greater operational importance. Revenue may benefit from:
- contracted institutional demand;
- temporary shortages affecting competitors;
- established DEA quota allocations;
- low-cost domestic or nearshore production;
- broad strength coverage; and
- reliable wholesaler fulfillment.
The principal financial risks are:
- declining prescription volume;
- generic price compression;
- product liability and opioid litigation;
- compliance costs;
- quota limitations;
- API shortages;
- manufacturing shutdowns; and
- payer substitution.
Opioid litigation has imposed significant financial liabilities across the pharmaceutical distribution and manufacturing ecosystem. Settlements involving opioid manufacturers and distributors have affected corporate cash flow, legal reserves, and strategic appetite for opioid products (U.S. Department of Justice, 2022).
How does hydrocodone acetaminophen compare with competing analgesics?
| Product category |
Volume trend |
Patent position |
Pricing power |
Main commercial risk |
| Hydrocodone/APAP immediate release |
Declining |
Expired/genericized |
Low |
Regulatory and liability exposure |
| Oxycodone/APAP immediate release |
Declining |
Genericized |
Low |
Opioid controls and substitution |
| Tramadol/APAP |
Mixed to declining |
Genericized |
Low |
Lower opioid utilization |
| Codeine/APAP |
Declining |
Genericized |
Low |
Safety and efficacy concerns |
| NSAIDs |
Established |
Mostly generic |
Low to moderate |
Safety restrictions |
| Acetaminophen alone |
Large mature market |
Genericized |
Low |
Commodity competition |
| Novel non-opioid analgesics |
Potential growth |
Often patent protected |
Higher initially |
Reimbursement and adoption |
Hydrocodone/APAP retains a role in acute pain because of prescriber familiarity and broad availability. It faces substitution from ibuprofen, naproxen, acetaminophen, local anesthetics, regional anesthesia, and newer non-opioid therapies. Generic oxycodone/APAP is the closest opioid combination comparator, while tramadol and codeine combinations compete in lower-intensity pain settings.
What is the outlook for hydrocodone acetaminophen through 2030?
The base-case outlook is a declining but persistent generic market.
| Period |
Expected market condition |
| 2024-2025 |
Mature demand, continued generic competition, intermittent supply pressure |
| 2026-2027 |
Further prescription contraction, greater non-opioid substitution |
| 2028-2030 |
Residual acute-pain demand, low pricing, selective value for efficient suppliers |
Revenue is likely to decline through volume and price pressure, with periodic increases caused by shortages or competitor exits. A sustained increase would require a structural supply disruption, a new differentiated formulation, or a significant change in prescribing policy. Neither a new broad patent cycle nor durable brand repricing is apparent for conventional immediate-release products.
Key Takeaways
- Hydrocodone bitartrate and acetaminophen is a mature, genericized U.S. opioid market.
- Vicodin, Norco, and Lortab no longer provide meaningful patent-based exclusivity.
- The standard immediate-release tablet market has low pricing power and fragmented supply.
- Prescription volume has fallen sharply since the early 2010s.
- DEA scheduling, FDA opioid policies, and state prescribing controls have reduced demand.
- Manufacturing capacity, quota access, API supply, and distribution are more important than patents.
- Paragraph IV litigation is no longer the central market issue for conventional tablets.
- Public companies generally do not disclose standalone hydrocodone/APAP revenue.
- Long-term financial performance is likely to show gradual decline with episodic shortage-driven volatility.
- Differentiated delivery or abuse-deterrent products could command stronger protection, but they would face adoption and reimbursement barriers.
FAQs
Is hydrocodone acetaminophen still patent protected?
Conventional immediate-release hydrocodone bitartrate and acetaminophen products are generally not protected by meaningful remaining composition or formulation exclusivity.
Is hydrocodone acetaminophen a generic drug?
Yes. Most currently dispensed products are approved generic products supplied by multiple manufacturers.
Can a generic manufacturer launch hydrocodone acetaminophen immediately?
FDA approval alone does not guarantee commercial launch. The manufacturer also needs controlled-substance quota, compliant production capacity, API supply, and distribution access.
Does hydrocodone acetaminophen have biosimilar competition?
No. Hydrocodone/APAP is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Competition occurs through ANDA-approved generic products.
Why can hydrocodone acetaminophen prices rise despite expired patents?
Temporary price increases can result from manufacturing disruptions, DEA quota limits, API shortages, recalls, wholesaler allocations, or competitors leaving the market. These increases are generally operational rather than patent-driven.
References
Centers for Disease Control and Prevention. (2016). CDC guideline for prescribing opioids for chronic pain: United States, 2016. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps and data. U.S. Department of Health and Human Services.
Drug Enforcement Administration. (2014). Schedules of controlled substances: Rescheduling of hydrocodone combination products from Schedule III to Schedule II. U.S. Department of Justice.
U.S. Department of Justice. (2022). Justice Department announces resolution of opioid-related claims against major pharmaceutical manufacturers and distributors. U.S. Department of Justice.
U.S. Food and Drug Administration. (2011). FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 mg of acetaminophen per dosage unit. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2016). Opioid action plan. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024b). Generic drug user fees and the ANDA approval process. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024c). Drug shortages and supply chain information. U.S. Department of Health and Human Services.
